NCT06629376View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

December 20, 2026

Study Completion Date

August 8, 2027

Conditions
GoutHyperuricemia
Interventions
DRUG

Pegylated Recombinant Candida Utilis Uricase for Injection

According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time

Trial Locations (1)

Unknown

RECRUITING

HuaShan Hospital Fudan University project, ShangHai, China, Shanghai

All Listed Sponsors
lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY